HASSELT, Belgium--(BUSINESS WIRE)--MabCure, Inc. (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, welcomes Dr. David S. Frank to the company’s board of directors.
